Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer's Disease and Coya's Pathway to a Pipeline in a Product -February 21, 2024 at 08:16 am EST

Combination biologics with LD IL-2 as a backbone may represent next-generation approaches that target complex immune pathways in neurodegenerative diseases



Expansion of COYA 302 into...

Related Keywords

Houston ,Texas ,United States ,Americans ,Howard Berman ,Jason Thonhoff ,David Beers ,Stanley Appel ,Nasdaq ,Additional Clinical Development Updates ,Coya Therapeutics Inc ,University Of Nebraska Medical Center ,Houston Methodist Research Institute ,National Institutes Of Health ,Centers For Disease ,Alzheimer Association ,Coya Therapeutics ,Chief Executive Officer ,Fellow Stockholders ,Amyotrophic Lateral Sclerosis ,Frontotemporal Dementia ,Double Blind Trial ,Proof Of Concept Study ,Houston Methodist Hospital ,Clinical Development Updates ,Nebraska Medical Center ,Granulocyte Macrophage Colony Stimulating Factor ,About Amyotrophic Lateral ,Lou Gehrig ,Disease Control ,Markets ,